🇺🇸 FDA
Patent

US 11530259

Therapies and methods to treat TLR2-mediated diseases and disorders

granted A61KA61K2039/505A61K31/60

Quick answer

US patent 11530259 (Therapies and methods to treat TLR2-mediated diseases and disorders) held by The Regents of the University of California expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K2039/505, A61K31/60, A61K39/39516, A61K39/39533